Physician profile
Daniel H Jacobs
NPI 1356323166
$38,463.07
in general payments reported to CMS, 2019-2025
79 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,389 · 2020: $3,573 · 2021: $3,641 · 2022: $5,453 · 2023: $7,524 · 2024: $3,301 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $8,375 · Travel and Lodging: $1,066 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,847.69 |
| Consulting Fee | $8,375.00 |
| Travel and Lodging | $1,065.81 |
| Education | $117.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $7,808.01 | 2019-2025 | Uplizna |
| Argenx US, INC. | $3,454.01 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Horizon Therapeutics Plc | $1,803.55 | 2021-2023 | Uplizna |
| Acadia Pharmaceuticals INC | $1,757.40 | 2019-2025 | Nuplazid, Daybue |
| Genzyme Corporation | $1,631.94 | 2019-2025 | |
| Abbvie INC. | $1,624.98 | 2020-2025 | |
| Biogen, INC. | $1,489.31 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Genentech USA, INC. | $1,467.96 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Evrysdi |
| Emd Serono, INC. | $1,294.31 | 2019-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $1,130.65 | 2019-2025 | |
| Allergan, INC. | $1,126.89 | 2019-2022 | |
| Banner Life Sciences, LLC | $963.49 | 2020-2023 | |
| Ucb, INC. | $886.77 | 2019-2025 | Rystiggo |
| Tg Therapeutics, INC. | $814.12 | 2023-2025 | |
| Lilly USA, LLC | $810.58 | 2019-2025 | Amyvid, Kisunla, Emgality |
Show all 75 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.